Ubrogepant Is Safe and Efficacious in Participants Taking Concomitant Preventive Medication for Migraine: A Pooled Analysis of Phase 3 Trials

INTRODUCTION: Ubrogepant is a calcitonin gene-related peptide receptor antagonist indicated for acute treatment of migraine that can be used to treat breakthrough attacks in individuals taking preventive treatment for migraine. We evaluated the impact of preventive medication use on the efficacy and...

Descripción completa

Detalles Bibliográficos
Autores principales: Blumenfeld, Andrew M., Knievel, Kerry, Manack Adams, Aubrey, Severt, Lawrence, Butler, Matthew, Lai, Hongxin, Dodick, David W.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799553/
https://www.ncbi.nlm.nih.gov/pubmed/34874514
http://dx.doi.org/10.1007/s12325-021-01923-3

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8799553/
https://www.ncbi.nlm.nih.gov/pubmed/34874514
http://dx.doi.org/10.1007/s12325-021-01923-3

Ejemplares similares